InflaRx vs Virax Biolabs
IFRX and VRAX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IFRX and VRAX compare
Virax Biolabs grew revenue faster over the last twelve months (96.2% versus −82.3% for InflaRx).
Virax Biolabs scores higher on the StockData Score (9 against 5 for InflaRx), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IFRX | VRAX |
|---|---|---|
| Size and price | ||
| Share price | $1.17 | $0.613 |
| Change, 1 year | −19.9% | −94.7% |
| Change, 5 years | −75.4% | – |
| Beta (5Y) | 1.47 | 1.61 |
| StockData Score | ||
| Total score | 5 | 9 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 3 (better) |
| Performance score | 0 | 1 (better) |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | −82.3% | 96.2% (better) |
| Revenue growth, 5Y average | – | −36.9% |
| Profitability | ||
| Gross margin | −24678% | 61.9% (better) |
| Operating margin | – | −51515% |
| Net margin | – | −40439% |
| FCF margin | – | −39264% |
| Return on equity | – | −75.7% |
| Return on invested capital | – | −388% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 4.13 | 9.97 (better) |
| Piotroski F-score | – | 6 |
| Ownership | ||
| Held by institutions | 135% | 0.00% |
| Held by insiders | 6.0% | 63.6% |
| Short interest, % of float | – | 3.2% |
Go deeper
- IFRX stock overview
- IFRX income statement
- IFRX valuation and score
- VRAX stock overview
- VRAX income statement
- VRAX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.